Table 2.
Association of 9 SNPs of the CCL5 and CCL5 signaling pathway with breast carcinomaa risk.
| SNP | Gene | Genotype | Risk allele frequency | Heterozygotesb | Homozygotesc | Per risk allele | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases (n = 544) | Controls (N = 538) | OR (95%CI) | P | OR (95%CI) | P | OR (95%CI) | P | |||
| rs2107538 | CCL5 | C/T | 0.206 | 0.149 | 1.36 (1.04–1.77) | 0.025** | 2.74 (1.337–5.60) | 0.004** | 1.47 (1.17–1.84) | 0.0007 |
| rs2280788 | CCL5 | G/C | 0.009 | 0.002 | 2.67 (0.70–10.11) | NS | 3.0 (0.12–73.81) | NS | 3.32 (0.91–12.09) | 0.054 |
| rs2280789 | CCL5 | A/G | 0.132 | 0.109 | 1.13 (0.85–1.51) | NS | 5.52 (1.12–23.69) | 0.019* | 1.25 (0.96–1.62) | 0.092 |
| rs614367 | CCND1 | C/T | 0.13 | 0.099 | 1.18 (0.87–1.59) | NS | 3.64 (1.19–11.16) | 0.016** | 1.38 (1.02–1.71) | 0.032 |
| rs704010 | ZMIZ1 | C/T | 0.321 | 0.288 | 1.01 (0.79–1.30) | NS | 1.51 (0.99–2.31) | NS | 1.15 (0.96–1.38) | NS |
| rs1045485 | CASP8 | G/C | 0.136 | 0.124 | 1.05 (0.79–1.41) | NS | 1.37 (0.62–3.03) | NS | 1.10 (0.85–1.41) | NS |
| rs1124933 | NOTCH2 | G/A | 0.319 | 0.339 | 0.80 (0.62–1.03) | NS | 0.90 (0.61–1.31) | NS | 0.90 (0.75–1.07) | NS |
| rs1294255 | MAP3K21 | G/C | 0.425 | 0.411 | 1.0 (0.77–1.31) | NS | 1.09 (0.78–1.52) | NS | 1.04 (0.88–1.23) | NS |
| rs1924587 | HS6ST3 | G/C | 0.427 | 0.369 | 1.33 (1.02–1.74) | 0.032* | 1.52 (1.07–2.17) | 0.021** | 1.26 (1.06–1.49) | 0.009 |
CI, confidence interval; OR, odds ratio.
a
Including all breast carcinoma patients.
b
Heterozygotes compared to homozygotes of reference allele.
c
Homozygotes of risk allele compared to homozygotes of reference allele.
The chi-square test with was used to determine whether significant differences (P-value) were observed when patient group was compared with control subjects. Significant P-values are in bold cases.
**
The association remains significant after age and menopausal status adjustment.
*
Not significant after age and menopausal status adjustment.